miR-141-3p is Poorly Expressed in Polycystic Ovary Syndrome and Correlates with Glucose and Lipid Metabolism
Table 4
Changes of clinical parameters in PCOS-obese patients during the 3-month intervention of fat reduction.
Parameters
PCOS-obese
Fat reduction intervention
value
(N = 43)
(N = 43)
BMI (kg/m2)
28.55 (25.43–30.60)
27.39(24.63–30.54)
0.04
WHR
0.92 (0.82–1.02)
0.85 (0.77–0.94)
<0.001
TG (mmol/L)
1.51 (1.04–2.21)
1.42 (0.93–1.99)
0.076
TC (mmol/L)
1.30 (0.91–1.89)
1.22 (0.71–1.80)
0.104
LDL-C (mmol/L)
2.52 (1.99–2.91)
2.01 (1.66–2.41)
<0.001
HDL-C (mmol/L)
0.64 (0.17–1.34)
0.60 (0.07–1.20)
0.286
FBG (mmol/L)
5.68 (4.73–6.61)
5.43 (4.46–6.54)
0.265
FINS (mIU/L)
16.75 (15.31–18.17)
9.41 (8.09–10.92)
<0.001
HbAlc (%)
5.67 (5.06–6.26)
5.55 (5.04–6.13)
0.445
HOMA-β
156.6 (142.12–170.83)
94.78 (84.4–106.63)
<0.001
HOMA-IR
4.19 (3.95–4.43)
2.31 (2.10–2.54)
<0.001
Note. BMI, body mass index; WHR, waist-to-hip ratio; TG, triglyceride; TC, total cholesterol; LDL-C, low density lipoprotein cholesterin; HDL-C, high density lipoprotein cholesterin; FBG, fasting blood glucose; FINS, fasting insulin; HbAlc, glycosylated hemoglobin; HOMA-β, homeostasis model assessment of beta cell function index; HOMA-IR, homeostasis model assessment of insulin resistance.
